| tenofovir disoproxil fumarate / Generic mfg. |
| Terminated | 2b | 297 | US, Canada, Europe, RoW | BMS-986001, Placebo matching with BMS-986001, Efavirenz, Sustiva®, Lamivudine, Epivir®, Tenofovir, Viread® | Bristol-Myers Squibb | HIV-1 Infection | 03/13 | 07/14 | | |
NCT01400412: Bone, Immunologic, and Virologic Effects of a Antiretroviral Regimen |
|
|
| Completed | 2b | 262 | US | Darunavir, Prezista, TMC-114, DRV, Ritonavir, Norvir, RTV, Tenofovir disoproxil fumarate, Viread, TDF, Emtricitabine, Emtriva, FTC, Coviracil, Placebo for Tenofovir disoproxil fumarate, Placebo for Maraviroc, Maraviroc, Celesentri, Selzentry | AIDS Clinical Trials Group, National Institute of Allergy and Infectious Diseases (NIAID) | HIV-1 Infection | 06/14 | 06/14 | | |
NCT00122512: Study of Tenofovir Disoproxil Fumarate (TDF) for Prevention of HIV |
|
|
| Terminated | 2a | 500 | RoW | Tenofovir Disoproxil Fumarate | FHI 360 | HIV Infections | | | | |
NCT01737359: A Safety and Efficacy Study of Amdoxovir in HIV-1 Treatment-experienced Subjects. |
|
|
| Terminated | 2a | 2 | RoW | amdoxovir 300 mg bid, DAPD, AMDX, amdoxovir 500 mg bid, tenofovir DF 300 mg qd, Viread | RFS Pharma, LLC | Human Immunodeficiency Virus Infection | 02/13 | 03/13 | | |
NCT00046033: Comparing Standard-Dose Versus Adjusted-Dose Lopinavir/Ritonavir Therapy in HIV-Infected Persons With Drug Resistance |
|
|
| Completed | 2 | 118 | US | Lopinavir/ritonavir, Ritonavir, Saquinavir, Tenofovir disoproxil fumarate, Amprenavir | National Institute of Allergy and Infectious Diseases (NIAID) | HIV Infections | 03/03 | | | |
NCT00122577: Efficacy and Safety of Tenofovir DF/Atazanavir Enhanced With Low Dose of Ritonavir in HIV-Infected Patients |
|
|
| Terminated | 2 | 50 | Europe | Tenofovir, Atazanavir, Ritonavir | French National Agency for Research on AIDS and Viral Hepatitis, Bristol-Myers Squibb, Gilead Sciences | HIV Infections | | 07/04 | | |
NCT00270556: Phase II Comparator Study of Substitution of Tenofovir or Abacavir Receiving Thymidine Analogue as Part of HAART. |
|
|
| Completed | 2 | 100 | Europe | tenofovir disoproxil fumarate, Abacavir | Gilead Sciences | HIV | | 10/04 | | |
RAVE, NCT00647946: Study to Evaluate Changes in Limb Fat When Switching From a Thymidine Analogue |
|
|
| Completed | 2 | 100 | Europe | tenofovir DF, abacavir 300mg twice daily | Gilead Sciences | Lipodystrophy | 10/04 | 02/06 | | |
NCT00033163: A Comparison of Adefovir and Tenofovir for the Treatment of Lamivudine-Resistant Hepatitis B Virus in People With HIV |
|
|
| Completed | 2 | 90 | US | Adefovir dipivoxil, Tenofovir disoproxil fumarate | National Institute of Allergy and Infectious Diseases (NIAID) | HIV Infections, Hepatitis B | | 05/05 | | |
NCT00027339: Using Drug Levels and Drug Resistance Testing to Select Effective Anti-HIV Drug Combinations in Patients With Drug-resistant HIV |
|
|
| Completed | 2 | 53 | US | lopinavir/ritonavir, indinavir sulfate, tenofovir disoproxil fumarate, ritonavir, fosamprenavir | National Institute of Allergy and Infectious Diseases (NIAID) | HIV Infections | | 06/05 | | |
NCT00002415: Safety and Effectiveness of Adding PMPA Prodrug to an Anti-HIV Drug Combination to Treat HIV-Infected Patients |
|
|
| Completed | 2 | 175 | US | Tenofovir disoproxil fumarate | Gilead Sciences | HIV Infections | | | | |
NCT00036452: A Study to Compare Anti-HIV Drugs Given Twice a Day or Once a Day, With or Without Direct Observation |
|
|
| Completed | 2 | 402 | US, RoW | lopinavir/ritonavir, emtricitabine, stavudine, tenofovir DF | National Institute of Allergy and Infectious Diseases (NIAID) | HIV Infections | | 01/06 | | |
NCT00122486: Study of Tenofovir Disoproxil Fumarate (TDF) for Prevention of HIV |
|
|
| Completed | 2 | 1200 | RoW | Tenofovir Disoproxil Fumarate | FHI 360 | HIV Infections | | 03/06 | | |
NCT00088309: Effect of Tenofovir DF on Bone Metabolism in Children |
|
|
| Completed | 2 | 50 | US | Eye exam, Oral exam, CT scan, Neuropsychological testing, Electrocardiogram, Echocardiogram | National Cancer Institute (NCI) | HIV Infections | | 05/06 | | |
NCT00038220: Effectiveness of ABT-378/Ritonavir Plus Lamivudine Plus Efavirenz Plus Tenofovir DF in HIV-Infected Patients |
|
|
| Completed | 2 | 40 | US | Lopinavir/ritonavir, Efavirenz, Lamivudine, Tenofovir DF | Abbott | HIV Infections | | | | |
NCT00102206: A Comparison of Two Anti-HIV Drug Regimens for Youth Who Have Failed Prior Therapy |
|
|
| Completed | 2 | 6 | US | Abacavir sulfate, Emtricitabine, Lamivudine, Lopinavir/ritonavir, Saquinavir, Tenofovir disoproxil fumarate, Zidovudine | National Institute of Allergy and Infectious Diseases (NIAID), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | HIV Infections | | 05/07 | | |
NCT00350272: Elvucitabine/Efavirenz/Tenofovir Versus Lamivudine/Efavirenz/Tenofovir in Human Immunodeficiency Virus (HIV)-1 Infected, Treatment-naive Participants |
|
|
| Completed | 2 | 76 | US | Elvucitabine, ACH-126,443, Lamivudine, 3TC, Tenofovir, Viread, Efavirenz, Sustiva | Alexion, Achillion, a wholly owned subsidiary of Alexion | HIV Infections | 08/07 | 04/09 | | |
NCT00119379: Effectiveness of Nucleoside Supplementation or Switch to Tenofovir in Reversing Fat Loss in HIV Infected Adults |
|
|
| Completed | 2 | 50 | US | NucleomaxX, uridine, Tenofovir Disoproxil Fumarate, TDF | National Institute of Allergy and Infectious Diseases (NIAID) | HIV Infections, Lipodystrophy, Metabolic Diseases, Nutrition Disorders | 10/08 | 10/08 | | |
NCT00131677: Extended Safety Study of Tenofovir Disoproxil Fumarate (TDF) Among HIV-1 Negative Men |
|
|
| Completed | 2 | 400 | US | tenofovir disoproxil fumarate, Viread, placebo | Centers for Disease Control and Prevention, San Francisco Department of Public Health, AIDS Research Consortium of Atlanta | HIV Infection | 08/09 | 08/09 | | |
2010-021651-79: Studio degli effetti immuno-virologici dell’interruzione di Maraviroc nei pazienti che stanno fallendo un regime contenente Maraviroc Viro-Immunologic Effects of Interrupting Maraviroc in Patients Failing a Maraviroc-containing Antiretroviral Treatment (The Maraviroc Short-Stop Study) |
|
|
| Terminated | 2 | 30 | Europe | Coated tablet, Capsule, hard, Film-coated tablet, Gastro-resistant capsule, hard, Tablet, Capsule, soft, CELSENTRI*60CPR RIV 150MG, EMTRIVA*1FL 30CPS 200MG, COMBIVIR*60CPR RIV 150MG+300MG, CELSENTRI*60CPR RIV 300MG, CELSENTRI*90CPR RIV 300MG, ATRIPLA*30CPR RIV600+200+245MG, EPIVIR*BLIST 30CPR RIV 300MG, KIVEXA*FL 30CPR RIV 600MG+300M, RETROVIR*60CPR 300MG, TRUVADA*30CPR RIV 200MG/245MG, VIDEX*30CPS GASTR 400MG, VIREAD*30CPR 245MG, ZERIT*56CPS 30MG, ZERIT*56CPS 40MG, INTELENCE*FL 120CPR 100MG, ZIAGEN*6BLISTER 10CPR 300MG, VIRAMUNE*60CPR 200MG, SUSTIVA*30CPR RIV 600MG BLIST, APTIVUS*FL 120CPS MOLLI 250MG, INVIRASE*FL 120CPR RIV 500MG, KALETRA*120CPR RIV 200MG+50MG, PREZISTA*120CPR RIV 300MG, REYATAZ*FL 60CPS 200MG, NORVIR*4FL 84CPS MOLLI 100MG, TELZIR*1FL 60CPR RIV 700MG, ISENTRESS*FL 60CPR RIV 400MG | FONDAZIONE CENTRO S. RAFFAELE DEL MONTE TABOR | patients affected by HIV in stable treatment with Maraviroc from at least 6 months pazienti adulti affetti da HIV in terapia stabile con Maraviroc da almeno 6 mesi, Diseases [C] - Virus Diseases [C02] | | | | |
| Completed | 2 | 68 | US | coformulated emtricitabine (FTC) and tenofovir disoproxil fumarate (TDF) as PrEP, Placebo, Many Men, Many Voices (3MV) | University of North Carolina, Chapel Hill, National Institute on Drug Abuse (NIDA), National Institute of Mental Health (NIMH) | HIV | 09/11 | 09/11 | | |
NCT00896051 / 2009-010887-41: TMC125-TiDP2-C238: An Exploratory Pharmacokinetics, Safety and Anti-HIV Activity Study of Etravirine (ETR) When Given With Boosted Atazanavir (ATV/Rtv) at Two Different Doses and 1 Nucleoside Reverse Transcriptase Inhibitor (NRTI) in Treatment Experienced HIV Patients |
|
|
| Completed | 2 | 50 | US, Europe, RoW | Atazanavir (ATV) 300 mg, Atazanavir (ATV) 400 mg, Ritonavir (rtv) 100 mg, Nucleo(side)/(tide) reverse transcriptase inhibitors (NRTIs), Etravirine (ETR) 200 mg, Tenofovir disoproxil fumarate (TDF) 300 mg | Janssen R&D Ireland | HIV Infections, Acquired Immunodeficiency Syndrome | 04/12 | 04/12 | | |
2008-004970-41: Phase II open-label randomized multicenter trial to compare the efficacy and safety of two different doses of raltegravir and efavirenz, all in combination with tenofovir and lamivudine, in naive HIV-1-infected patients receiving rifampin for active tuberculosis. |
|
|
| Ongoing | 2 | 15 | Europe | Sustiva, Viread, Epivir, MK-0518, BMS-561525, raltegravir, Sustiva, Viread, Epivir, Isentress, Sustiva, Viread, Epivir, Isentress | Agence nationale de recherches sur le sida et les hépatites virales. ANRS. | HIV-1 Infection and tuberculosis | | | | |
NCT01903031: Evaluating Pharmacokinetic Interactions With Vaginal Ring Contraceptives and ART |
|
|
| Completed | 2 | 84 | US, RoW | Nuvaring, Etonogestrel/ethinyl estradiol vaginal ring, EFV, Efavirenz, ATV/r, Atazanavir/Ritonavir, TDF, Tenofovir Disoproxil Fumarate, NRTIs, Nucleoside Reverse Transcriptase Inhibitor | AIDS Clinical Trials Group, National Institute of Allergy and Infectious Diseases (NIAID) | HIV-1 Infection | 10/16 | 10/16 | | |
NCT00799864 / 2008-001696-30: A Study to Evaluate the Pharmacokinetics, Safety, Tolerability, and Antiviral Activity of Rilpivirine (TMC278) in Human Immunodeficiency Virus Infected Adolescents and Children Aged Greater Than or Equal to 6 Years |
|
|
| Completed | 2 | 54 | Europe, US, RoW | Rilpivirine, Zidovudine, Abacavir, Tenofovir disoproxil fumarate, Lamivudine, Emtricitabine | Janssen Sciences Ireland UC | HIV-1 | 08/22 | 08/22 | | |
NCT00002396: The Safety and Effectiveness of PMPA Prodrug in HIV-Infected Patients |
|
|
| Unknown status | 1/2 | 60 | US | Tenofovir disoproxil fumarate | Gilead Sciences | HIV Infections | | | | |
NCT00260078: Blood Levels of Anti-HIV Drugs Used in Combination Regimens in HIV Infected Children |
|
|
| Completed | 1/2 | 75 | US | Atazanavir, ATV, Darunavir, DRV, Efavirenz, EFV, Nevirapine, NVP, Ritonavir, RTV, Tenofovir disoproxil fumarate, TDF, Pharmacokinetic Study, PK Study | National Institute of Allergy and Infectious Diseases (NIAID), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | HIV Infections | 04/09 | 04/09 | | |
